D. Boral Capital Reaffirms “Buy” Rating for Quince Therapeutics (NASDAQ:QNCX)

Quince Therapeutics (NASDAQ:QNCX)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $12.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. EF Hutton Acquisition Co. I raised Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. Brookline Capital Management started coverage on Quince Therapeutics in a report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target for the company. Maxim Group started coverage on Quince Therapeutics in a research report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price objective for the company. RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Finally, Rodman & Renshaw started coverage on Quince Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $9.50.

Quince Therapeutics Price Performance

Shares of NASDAQ QNCX opened at $1.58 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The stock has a fifty day moving average price of $1.81 and a 200 day moving average price of $1.27. Quince Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.45. The company has a market cap of $69.52 million, a PE ratio of -1.27 and a beta of 0.61.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of Quince Therapeutics by 24.2% in the third quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock valued at $263,000 after buying an additional 66,170 shares in the last quarter. Scharf Investments LLC purchased a new position in shares of Quince Therapeutics in the fourth quarter valued at $170,000. Finally, Anfield Capital Management LLC purchased a new position in shares of Quince Therapeutics in the fourth quarter valued at $50,000. Hedge funds and other institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.